Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David A. Eavarone
Observed names:
D. Eavarone,
David Eavarone
Institution:
Siamab Therapeutics (United States)
Observed institutions:
Brigham and Women's Hospital,
Harvard University,
Massachusetts General Hospital,
Harvard–MIT Division of Health Sciences and Technology,
Siamab Therapeutics (United States),
Case Western Reserve University,
Massachusetts Institute of Technology
show all 7
ORCID:
0000-0003-3999-4404
Observed ORCID:
0000-0003-3999-4404
OpenAlex ID:
A5088615842
Works
17
Awards
1
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
2005
·
Shiladitya Sengupta
, David Eavarone
, et al.
·
Nature
·
1,020
Targeted drug delivery to C6 glioma by transferrin-coupled liposomes
2000
·
David A. Eavarone
, Xiaojun Yu
, et al.
·
Journal of Biomedical Materials Research
·
136
Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity
2017
·
Jillian M. Prendergast
, Ana Paula Galvao da Silva
, et al.
·
mAbs
·
85
PDF
Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma
2018
·
David A. Eavarone
, Linah Al-Alem
, et al.
·
PLoS ONE
·
45
PDF
Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau
2018
·
Kristen Starbuck
, Linah Al-Alem
, et al.
·
Oncotarget
·
34
PDF
Glycome and Transcriptome Regulation of Vasculogenesis
2009
·
Rania Harfouche
, Dirk M. Hentschel
, et al.
·
Circulation
·
30
PDF
A Voxel-Based Monte Carlo Model of Drug Release from Bulk Eroding Nanoparticles
2010
·
David A. Eavarone
, Venkataramanan Soundararajan
, et al.
·
Journal of Nanoscience and Nanotechnology
·
8
Abstract 3640: Novel humanized anti-Sialyl-Tn, anti-CD3 bispecific antibodies demonstrate tumor and T-cell specificity for immune activation at the tumor site
2017
·
David A. Eavarone
, Jillian Prendergast
, et al.
·
Cancer Research
·
3
Abstract 5625: Myeloid derived suppressor cells (MDSCs) express Sialyl Tn (STn) and are a therapeutic target for anti-STn antibody drug conjugates
2018
·
David A. Eavarone
, Patricia E. Rao
, et al.
·
Cancer Research
·
1
Eradicating ovarian cancer stem cells by targeting the tumor-associated carbohydrate antigen sialyl Tn
2015
·
K. Starbuck
, D. Eavarone
, et al.
·
Gynecologic Oncology
·
1
A novel nanoscale delivery system for spatio-temporal delivery of combination chemotherapy
2009
·
David A. Eavarone
·
DSpace@MIT (Massachusetts Institute of Technology)
·
1
PDF
Abstract B28: Targeting the tumor-associated carbohydrate antigen STn with humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibits ovarian cancer tumor growth in vitro and in vivo
2018
·
Daniel T. Dransfield
, Jillian M. Prendergast
, et al.
·
Clinical Cancer Research
Abstract B114: Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo
2018
·
Daniel Dransfield
, Jillian M. Prendergast
, et al.
·
Molecular Cancer Therapeutics
Abstract 36: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificity in vitro and in vivo antitumor efficacy
2017
·
Jillian M. Prendergast
, David A. Eavarone
, et al.
·
Cancer Research
Abstract MIP-071: TARGETING A CHEMORESISTANT OVARIAN CANCER CELL POPULATION VIA THE CARBOHYDRATE ANTIGEN SIALYL TN
2017
·
B.R. Rueda
, K. Starbuck
, et al.
·
Clinical Cancer Research
Vasculogenesis, a story of glycome and transcriptomal regulation
2009
·
Rania Harfouche
, Dirk M. Hentschel
, et al.
·
The FASEB Journal
A novel nanodelivery system for combination tumor therapy
2004
·
David A. Eavarone
·
DSpace@MIT (Massachusetts Institute of Technology)
Show more works
View as search
Works count:
17
Citation count:
1,364
H-index:
7
I10-index:
6
Year
Topic
Type